Silence Therapeutics PLC Update on litigation matters (8685W)
20 November 2017 - 6:00PM
UK Regulatory
TIDMSLN
RNS Number : 8685W
Silence Therapeutics PLC
20 November 2017
Update on litigation matters
20 November 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces an update on litigation matters.
Previously, Alnylam UK Limited and The Medicines Company UK Limited
sued to revoke the relevant Silence European patent EP 2 258 847B
in the UK, and also included claims for declarations of
non-infringement of EP 2 258 847B by certain Alnylam products.
Silence has now served its Defence in the actions initiated by
Alnylam and The Medicines Company and has counterclaimed for
threatened infringement of the Silence European patent EP 2 258
847B by these companies. If successful, products including
patisiran, fitusiran, givosiran and inclisiran will be found to
infringe EP 2 258 847B.
Further, Silence notes that Alnylam and The Medicines Company
are yet to serve their respective Defences in relation to the
earlier served action brought by Silence for a declaration as to
its entitlement to claim SPC protection on products containing the
above-named active substances.
Silence continues to regard these actions from all parties as
simply "normal course of business" at the commencement of
litigation, and continues to believe that certain Alnylam products
require a licence under the Silence patent estate.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics,
commented:
"We continue to believe that our fundamental chemical
modification technology is core foundational innovation for today's
RNAi sector, and that therefore those companies using such
modification technology within the scope of our Intellectual
Property (IP) will require a licence."
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20
Ali Mortazavi, Chief Executive 3457 6900
Officer
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser Tel: +44 (0)20
and Broker) 7418 8900
James Steel/Oliver Jackson
Media Enquiries: Tel: +44 (0)
FTI Consulting 20 3727 1000
Simon Conway/Brett Pollard/Stephanie
Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGGGGGGUPMGCM
(END) Dow Jones Newswires
November 20, 2017 02:00 ET (07:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2023 to Apr 2024